A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

CLL (Chronic Lymphocytic Leukemia) Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms SLL (Small Lymphocytic Lymphoma)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 years or older.
Diagnosis of CLL or SLL:

History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and
Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-

Exclusion criteria

Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.
Active and uncontrolled autoimmune cytopenia(s).

Treatment and study plan

MS-553, DS1

Drug

Oral, Dose Schedule 1

MS-553, DS2

Drug

Oral, Dose Schedule 2

Primary outcomes

The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings

Time frame: Through study completion, an average of 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Kai Zhang

CONTACT

[email protected]

858-699-7681

Sponsors and collaborators

Lead sponsor

MingSight Pharmaceuticals, Inc

Industry

Registry information

Official study title

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Important dates

Study start: 2026
Primary completion: 2028
Study completion: 2028
First posted: May 18, 2025
Registry last updated: Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting